GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator

Uridine 5'diphospho‐glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract

“…8 In UUTUC, however, UGT1A expression inversely correlated only with pT stage, but not tumor grade. 16 In contrast, in our recent studies, RPTs showed lower positive rates of other transcription factors, such as androgen receptor known to promote urothelial tumor outgrowth 7,25 (11.1% vs 28.0%, P = 0.070), 17 estrogen receptorb that could inhibit urothelial tumor outgrowth 8,25 (51.1% vs 72.0%, P = 0.056), 17 GATA3 shown to function as a tumor suppressor 26,27 (35.6% vs 66.0%, P = 0.004) 28 and Wound-healing assay in UMUC3-control-siRNA versus UMUC3-UGT1A-siRNA. Loss or weak expression of UGT1A was also associated with the presence of other known prognostic factors, such as lymphovascular invasion and concomitant CIS, but not lymph node metastasis or hydronephrosis.…”

ZKSCAN3 expression in urothelial carcinoma of the upper urinary tract and its impact on patient outcomes

“…42% in bladder tumors [10] vs. 28% in ureteral tumors [8] vs. 11% in renal pelvic tumors [8]) as well as another transcription factor GATA3 (i.e. 86% in bladder tumors [11] vs. 68% in ureteral tumors [12] vs. 36% in renal pelvic tumors [12]) we stained using the same protocol with identical antibodies. Meanwhile, we found no significant correlations of ZKSCAN3 expression with tumor grade or stage in both UUTUC and bladder cancer.…”

Clinical implication of the mammalian target of rapamycin pathway in upper tract urothelial carcinoma with negative GATA binding protein 3 expression

“…In BC, GATA3 has been reported as a marker for the luminal subtype, and molecular subtyping by immunohistochemistry of only GATA3 achieved sensitivity and specificity of 75% and 93% . We have shown the importance of GATA3 for UTUC . Therefore, we studied the implication of the mTOR pathway in the subtyping with GATA3 for UTUC.…”

“…The cohort included 99 Japanese patients with non‐metastatic UTUC who underwent radical nephroureterectomy between 1997 and 2011 at Osaka General Medical Center, Osaka City, Osaka, Japan. All sections were reviewed by a urological pathologist, and tissue microarray was constructed of representative paraffin block, as previously described . Immunohistochemistry was carried out for GATA3 and the following mTOR pathway members: PTEN, phos‐MTOR, phos‐AKT, phos‐4EBP1 (cytoplasmic and nuclear) and phos‐S6.…”

“…AKT‐regulated markers p27 and c‐MYC were also evaluated. The detailed protocol for immunohistochemistry has been previously reported . We categorized tumors with positive GATA3 staining as the luminal subtype, and tumors without GATA3 as the basal subtype.…”